Apollo Health Ventures raised $180 million for a new venture capital fund focused on biotechnology companies developing therapies for age-related diseases. It may also invest in healthtech and digital health opportunities, but the latter constitute a minority pursuit for an investment team that is building up capabilities and expertise in disease biology.
Virtual Incision Corp. raised $46 million in a series C funding round to support commercialization of its miniaturized in vivo robotic assistant (MIRA) for laparoscopic surgery. The first member of the company’s family of mini-robots in development targets colon surgery. Others in the pipeline will address hernia repair, gallbladder removal, sleeve gastrectomy, hysterectomy and other surgeries with specialized ranges of motion and tools.
PERTH, Australia – Medtech newcomer Artrya Ltd. listed on the Australian Securities Exchange (ASX) in an AU$40 million (US$28.6 million) initial public offering to commercialize its software that analyzes heart computed tomography (CT) scans via artificial intelligence (AI) to better diagnose coronary artery disease.
Biopharmas in Asia-Pacific raising money in public or private financings: Ablaze, Beigene, Bionomics, Greenlight, Help, Incannex Healthcare, Neurophth, Serum Institute of India.
LONDON – Quell Therapeutics Ltd. has raised $156 million in an oversubscribed series B, enabling it to start a phase I/II trial of its engineered T regulatory (Treg) cell therapy for promoting long-term immune tolerance in liver transplant patients, averting the need for chronic immunosuppression.
Ilex Medical Ltd. has injected $3.2 million into cell therapy company Kadimastem Ltd., as it prepares to list on the Nasdaq. As part of the investment, Ilex Medical was granted a total of 1,407,130 options (60% coverage) in two series, at exercise prices of $2.2 and $2.7 per share (up to 100% from the share price at the transaction). If exercised, it would increase the total investment to $6.7 million.
Lunit Inc. has raised $61 million in a fundraising round, getting it closer to its planned list on South Korea’s Kosdaq. “We will use these funds as working capital to research and develop artificial intelligence (AI) products, as well as developing our global market,” a Lunit spokesperson told BioWorld. Seoul, South Korea-based Lunit secured new investors for this round, including U.S. life science investors Healthquest Capital, Casdin Capital LLC, and The American Cancer Society’s Brightedge fund. Asia Pacific-based global health care investors included Tybourne Capital Management Ltd. and NSG Ventures Pte. Ltd.
RSS
